Bone Metastases in Patients with Metastatic Renal Cell Carcinoma: Are They Always Associated with Poor Prognosis?

Purpose: Aim of this study was to investigate for the presence of existing prognostic factors in patients with bone metastases (BMs) from RCC since bone represents an unfavorable site of metastasis for renal cell carcinoma (mRCC).

Materials And Methods: Data of patients with BMs from RCC were retrospectively collected. Age, sex, ECOG-Performance Status (PS), MSKCC group, tumor histology, presence of concomitant metastases to other sites, time from nephrectomy to bone metastases (TTBM, classified into three groups: <1 year, between 1 and 5 years and >5 years) and time from BMs to skeletal-related event (SRE) were included in the Cox analysis to investigate their prognostic relevance.

Results: 470 patients were enrolled in this analysis. In 19 patients (4%),bone was the only metastatic site; 277 patients had concomitant metastases in other sites. Median time to BMs was 16 months (range 0 - 44y) with Median OS of 17 months. Number of metastatic sites (including bone, p = 0.01), concomitant metastases, high Fuhrman grade (p < 0.001) and non-clear cell histology (p = 0.013) were significantly associated with poor prognosis. Patients with TTBM >5 years had longer OS (22 months) compared to patients with TTBM <1 year (13 months) or between 1 and 5 years (19 months) from nephrectomy (p < 0.001), no difference was found between these two last groups (p = 0.18). At multivariate analysis, ECOG-PS, MSKCC group and concomitant lung or lymph node metastases were independent predictors of OS in patients with BMs.

Conclusions: Our study suggest that age, ECOG-PS, histology, MSKCC score, TTBM and the presence of concomitant metastases should be considered in order to optimize the management of RCC patients with BMs.

Citing Articles

Characteristics and Outcomes of T1a Renal Cell Carcinoma Presenting with Metastasis.

Wang L, Guer M, Puri D, Liu F, Dhanji S, Meagher M Cancers (Basel). 2025; 17(3).

PMID: 39941733 PMC: 11815727. DOI: 10.3390/cancers17030364.

Practical management of renal cell carcinoma: integrating current approaches with advances in bone metastasis treatment.

Eremia I, Serban B, Popa M, Iancu A, Nica S, Cirstoiu C EFORT Open Rev. 2024; 9(6):488-502.

PMID: 38828980 PMC: 11195343. DOI: 10.1530/EOR-23-0178.

Therapeutic options for different metastatic sites arising from renal cell carcinoma: A review.

Wang X, Qian L, Qian Z, Wu Q, Cheng D, Wei J Medicine (Baltimore). 2024; 103(21):e38268.

PMID: 38788027 PMC: 11124732. DOI: 10.1097/MD.0000000000038268.

Predictive factors of nivolumab plus ipilimumab treatment efficacy in metastatic renal cell carcinoma patients.

Ohba K, Nakanishi H, Kawada K, Nakamura Y, Mitsunari K, Matsuo T Jpn J Clin Oncol. 2024; 54(7):827-832.

PMID: 38651176 PMC: 11228832. DOI: 10.1093/jjco/hyae046.

A dynamic visualization clinical tool constructed and validated based on the SEER database for screening the optimal surgical candidates for bone metastasis in primary kidney cancer.

Jiang L, Tong Y, Wang J, Jiang J, Gong Y, Zhu D Sci Rep. 2024; 14(1):3561.

PMID: 38347099 PMC: 10861469. DOI: 10.1038/s41598-024-54085-x.

References

Athar U, Gentile T . Treatment options for metastatic renal cell carcinoma: a review. Can J Urol. 2008; 15(2):3954-66. View

Santini D, Procopio G, Porta C, Ibrahim T, Barni S, Mazzara C . Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. PLoS One. 2014; 8(12):e83026. PMC: 3875424. DOI: 10.1371/journal.pone.0083026. View

Mundy G . Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2(8):584-93. DOI: 10.1038/nrc867. View

Murai M, Oya M . Renal cell carcinoma: etiology, incidence and epidemiology. Curr Opin Urol. 2004; 14(4):229-33. DOI: 10.1097/01.mou.0000135078.04721.f5. View

Santoni M, Santini D, Massari F, Conti A, Iacovelli R, Burattini L . Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. Cancer Metastasis Rev. 2013; 33(1):321-31. DOI: 10.1007/s10555-013-9453-5. View

Sahi C, Knox J, Clemons M, Joshua A, Broom R . Renal cell carcinoma bone metastases: clinical advances. Ther Adv Med Oncol. 2011; 2(2):75-83. PMC: 3126010. DOI: 10.1177/1758834009358417. View

Fizazi K, Yang J, Peleg S, Sikes C, Kreimann E, Daliani D . Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res. 2003; 9(7):2587-97. View

Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger M, Sinibaldi V . Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur J Cancer. 2012; 48(7):1031-7. DOI: 10.1016/j.ejca.2012.02.050. View

Motzer R, Bander N, Nanus D . Renal-cell carcinoma. N Engl J Med. 1996; 335(12):865-75. DOI: 10.1056/NEJM199609193351207. View

10.

Satcher R, Pan T, Cheng C, Lee Y, Lin S, Yu G . Cadherin-11 in renal cell carcinoma bone metastasis. PLoS One. 2014; 9(2):e89880. PMC: 3933681. DOI: 10.1371/journal.pone.0089880. View

11.

Chirgwin J, Guise T . Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr. 2001; 10(2):159-78. View

12.

Heng D, Xie W, Regan M, Warren M, Golshayan A, Sahi C . Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27(34):5794-9. DOI: 10.1200/JCO.2008.21.4809. View

13.

Woodward E, Jagdev S, McParland L, Clark K, Gregory W, Newsham A . Skeletal complications and survival in renal cancer patients with bone metastases. Bone. 2010; 48(1):160-6. DOI: 10.1016/j.bone.2010.09.008. View

14.

Motzer R, Bacik J, Schwartz L, Reuter V, Russo P, Marion S . Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004; 22(3):454-63. DOI: 10.1200/JCO.2004.06.132. View

15.

Santoni M, Conti A, Porta C, Procopio G, Sternberg C, Basso U . Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. J Urol. 2014; 193(1):41-7. DOI: 10.1016/j.juro.2014.07.011. View

16.

McKay R, Lin X, Perkins J, Heng D, Simantov R, Choueiri T . Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur Urol. 2014; 66(3):502-9. PMC: 4145043. DOI: 10.1016/j.eururo.2014.02.040. View

17.

Gerlinger M, Rowan A, Horswell S, Math M, Larkin J, Endesfelder D . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892. PMC: 4878653. DOI: 10.1056/NEJMoa1113205. View

18.

Beuselinck B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J . Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol. 2010; 22(4):794-800. DOI: 10.1093/annonc/mdq554. View

19.

Yang L, You S, Kumar V, Zhang C, Cao Y . In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line. J Exp Clin Cancer Res. 2012; 31:40. PMC: 3511813. DOI: 10.1186/1756-9966-31-40. View

20.

Chen Y, Liu H, Wu W, Li Y, Li J . Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis. J Exp Clin Cancer Res. 2013; 32:45. PMC: 3728114. DOI: 10.1186/1756-9966-32-45. View